Evidence map›Paper›PMID 29731394›Full record

ArticleCancer cell2018

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Matthew D Hellmann, Margaret K Callahan, Mark M Awad, Emiliano Calvo, Paolo A Ascierto, Akin Atmaca, Naiyer A Rizvi, Fred R Hirsch, Giovanni Selvaggi, Joseph D Szustakowski and 6 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03894215 (A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034), which is not on this map. Cited by 527 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
527citing papers in PubMed, 7 pooled it
52.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03894215 phase2terminatednot on this mapstarted 2019, after this paper: background citation

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

TypeinterventionalSponsorAgenus Inc.Ran2019 to 2025Enrolled211ConditionsCervical CancerArmsAGEN2034, AGEN1884
3 · Its place in the literature

Who cites it

527 citing papers in PubMed, 7 syntheses or guidelines pooled it, 886 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Trial
  16. Trial
  17. Review
  18. Review
  19. Article
  20. Article

467 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Matthew D HellmannThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, 885 2nd Avenue, New York, NY 10017, USA. Electronic address: hellmanm@mskcc.org.
Margaret K CallahanThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, 885 2nd Avenue, New York, NY 10017, USA.
Mark M AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Emiliano CalvoSTART Madrid, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Madrid 28050, Spain.
Paolo A AsciertoUnit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples 80131, Italy.
Akin AtmacaDepartment of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main 60488, Germany.
Naiyer A RizviDivision of Hematology and Oncology, Columbia University Medical Center, New York, NY 10032, USA.
Fred R HirschDepartment of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Giovanni SelvaggiClinical Development, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Joseph D SzustakowskiTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Ariella SassonTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Ryan GolharTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Patrik VitazkaTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Han ChangTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
William J GeeseTranslational Medicine, Bristol-Myers Squibb, Princeton, NJ 08648, USA.
Scott J AntoniaDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Bristol-Myers Squibb (United States) · USMemorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USGoethe University Frankfurt · DEHospital Universitario HM Sanchinarro · ESIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITMoffitt Cancer Center · USUniversity of Colorado Anschutz Medical Campus · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032. Patients received nivolumab (3 mg/kg every 2 weeks) or nivolumab plus ipilimumab (1 mg/kg plus 3 mg/kg every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks). Efficacy of nivolumab ± ipilimumab was enhanced in patients with high tumor mutational burden. Nivolumab plus ipilimumab appeared to provide a greater clinical benefit than nivolumab monotherapy in the high tumor mutational burden tertile.

Indexed as

MutationAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, DrugDrug Administration ScheduleExome SequencingFemaleHumansIpilimumabLung NeoplasmsMaleMiddle AgedNivolumabSmall Cell Lung CarcinomaIpilimumabNivolumabbiomarkersclinical trialCTLA-4immunotherapyipilimumabnivolumabPD-1small cell lung cancertumor mutation burden

Identifiers

PMID29731394
PMCPMC6750707
OpenAlexW2800160190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.